OTCMKTS:VACBF Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis $0.30 0.00 (0.00%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Nykode Therapeutics AS Stock (OTCMKTS:VACBF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nykode Therapeutics AS alerts:Sign Up Key Stats Today's Range$0.30▼$0.3050-Day Range$0.30▼$0.4552-Week Range$0.30▼$0.45VolumeN/AAverage Volume1,000 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nykode Therapeutics AS is a Norwegian biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. Formerly known as Vaccibody, the company adopted the Nykode name in 2021. Its research is based on a modular vaccine platform designed to direct antigens to antigen-presenting cells, with the aim of generating targeted immune responses. The platform supports programs including therapeutic cancer vaccines and vaccines for infectious diseases, with candidates evaluated in clinical development. Based in Oslo, Nykode conducts research and development in Norway and works with international partners to advance its programs. Its work includes collaborations with pharmaceutical companies and clinical research conducted across multiple regions.AI Generated. May Contain Errors. Read More Receive VACBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nykode Therapeutics AS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VACBF Stock News HeadlinesNykode’s Abi-Suva Potential and 2027 Catalysts Support a Buy RatingNovember 5, 2026 | tipranks.comNykode Therapeutics AS (VACBF) Q4 2025 Earnings Call TranscriptFebruary 25, 2026 | seekingalpha.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 16 at 1:00 AM | Paradigm Press (Ad)Nykode Therapeutics AS (VACBF) Q3 2025 Earnings Call TranscriptNovember 24, 2025 | seekingalpha.comNykode Therapeutics AS (VACBF) Q2 2025 Earnings Call Highlights: From Net Loss to Profit Amid ...August 28, 2025 | finance.yahoo.comVACBF | Nykode Therapeutics A/S Annual Cash Flow Statement - MarketWatchJuly 2, 2025 | marketwatch.comVACBF Nykode Therapeutics AS - Seeking AlphaJuly 1, 2025 | seekingalpha.comNykode Therapeutics AS (VACBF) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comSee More Headlines VACBF Stock Analysis - Frequently Asked Questions How have VACBF shares performed this year? Nykode Therapeutics AS's stock was trading at $0.1558 at the beginning of the year. Since then, VACBF stock has increased by 90.9% and is now trading at $0.2974. How do I buy shares of Nykode Therapeutics AS? Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:VACBF CIKN/A Webnykode.com Phone47-22-95-81-93FaxN/AEmployees171Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:VACBF) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nykode Therapeutics AS Please log in to your account or sign up in order to add this asset to your watchlist. Share Nykode Therapeutics AS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.